Mutual Advisors LLC Buys 20,583 Shares of Pfizer Inc. (NYSE:PFE)

Mutual Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE) by 10.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 221,393 shares of the biopharmaceutical company’s stock after purchasing an additional 20,583 shares during the period. Mutual Advisors LLC’s holdings in Pfizer were worth $5,610,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PFE. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the 4th quarter valued at $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer in the fourth quarter worth about $27,000. Gould Capital LLC grew its stake in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer during the 4th quarter valued at about $30,000. Finally, Curio Wealth LLC bought a new position in shares of Pfizer in the 4th quarter worth approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Up 1.1%

NYSE PFE opened at $25.32 on Thursday. The stock has a 50 day moving average price of $23.62 and a 200-day moving average price of $24.83. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a market capitalization of $143.95 billion, a P/E ratio of 18.35, a P/E/G ratio of 0.91 and a beta of 0.58.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the business earned $0.82 earnings per share. Pfizer’s quarterly revenue was down 7.8% compared to the same quarter last year. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.79%. Pfizer’s payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.